

# ASX Release

---

## **SUDA ANNOUNCES RESIGNATION OF MICHAEL STEWART FROM THE BOARD**

**PERTH, AUSTRALIA – 10 April 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today announces that its Chairman, Mr. Michael (Mike) Stewart, has resigned from the Board of SUDA Pharmaceuticals Ltd for personal reasons.

Mike has worked tirelessly for shareholders in his role as Chairman for the past nine years and he has played an integral part in repositioning SUDA and dealing with a range of legacy issues inherited by the Company.

Over the past few years, Mike has been under tremendous pressure after his wife unexpectedly suffered a spinal stroke that has left her wheelchair bound.

In a statement, Mr. Stewart advised that he needs to turn his full attention to supporting his wife as they both come to terms with the full impact of what has occurred. This personal issue needs to take strict priority for Mike from now.

Mike will continue to provide the Company with support and has offered to be available for consultation on specific issues as needed.

The Company has commenced a search for a new Chairperson. In the interim, SUDA's CEO, Mr. Stephen Carter, has been appointed Executive Chairman.

Mr. Stephen Carter, commented: "Mike Stewart has made a substantial contribution to SUDA during his tenure as Chairman. However, we understand the tragic circumstances that have instigated his resignation and we offer Mike and his wife, Lyn, our best wishes for the future. SUDA is going through a period of change and we anticipate expanding the Board further with relevant experience."



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 8 6142 555  
[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)